New clinical trial data comparing cervical cancer screening methods led to the recent FDA approval of an HPV DNA test as a primary screen in women 25 and older—just the latest development in this dynamic area of laboratory testing. Join AACC for this 60-minute FREE webinar, supported by an educational grant from Roche Diagnostics, and hear Mark H. Stoler, MD, discuss the new data and what it means for the future of cervical cancer screening, what constitutes a "clinically validated" HPV test, and what the advantages and limitations of using today's FDA-cleared HPV testing technologies are in the context of these new developments.
Speaker Presentation Description
Mark H. Stoler, MD, Professor (Emeritus) of Pathology, Cytology and Gynecology; and Director, Gynecological Pathology Fellowship Program, University of Virginia, Charlottesville, VA
Laboratory administrators, directors, and managers; cytopathologists; molecular pathologists; clinicians; and IVD industry professionals involved in cervical cancer screening or HPV testing.